Device Trial Radar · NCT03065881
RETeval All Comers Trial (REACT)
Last checked: Nov 20, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
664
Actual
Start
Feb 13, 2017
Primary completion
Dec 21, 2021
Study completion Dec 21, 2021
Sponsor
- Lead sponsor
- LKC Technologies, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 28, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Screening
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 6 months, up to 95 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to collect electroretinogram ERG measurements from visually normal and abnormal subjects using the FDA cleared RETeval device (K142567). Data from the visually normal subjects will be used to create reference intervals for the device. Secondary objectives of the study are to provide ERG waveforms representative of disease states encountered and to analyze how well an ERG detects the various disease states encountered.
Conditions
- Retinal Disease, Electroretinogram
Interventions
RETevalDevice
The RETeval device measures the retina's electrical response to light, called an electroretinogram (ERG). The standards body ISCEV \[1\] recommends collecting normative data for ERGs to provide waveforms and statistically relevant measurements representing the range of ERGs from people with normal vision. LKC Technologies provides this information with their UTAS product line and wishes to collect such a database for the newest device: the RETeval device. As the RETeval device uses a different electrode to measure the ERG, the normal data for the UTAS product line is not transferable to the RETeval device. Ophthalmic practitioners would also like ERG examples of specific retinal disorders to help diagnose patients with abnormal ERGs. The RETeval device is FDA cleared (K142567),
Primary outcomes
What the sponsor says the trial is designed to measure.
- Retinal function assessed with an electroretinogram (ERG)Time frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Little Rock Eye Clinic
Little Rock, Arkansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.